IPD
IMPEDIMED FPO [IPD]
Healthcare · ASX Small Cap
$0.0060 +20.0%
Updated 9 Sep 2026 · Signals refresh every scan
Appeared in 3 consecutive scansFirst seen: 2026-04-13
Get alerts when IPD triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Active Signals
Bullish Signals
- MACD just crossed bullish — momentum is shifting to the upside
- Pressing against the upper Bollinger Band — extended and may need to cool off
- Knocking on the door of resistance — if it punches through, things could get interesting
- On a tear — up 20.0% over the last 5 days
- Beating the Small Ords index — relative strength of 1.23, so it's outpacing the pack
- Low cash runway (3 quarters) - dilution risk
- Low P/S ratio (1.3x)
- Moderate revenue growth (+6%)
- EPS estimates revised upward (+10pts)
- Near 52-week low (4% of range)
- Micro-cap ($5-20M) - high risk
- CANSLIM I: Institutional ownership (21%)
- Sentiment is mixed — no strong consensus either way
- This one has been in freefall — down 86% over the past year
- The bigger volume days are the up days — volume-weighted momentum is positive (1.84%/day)
- Altman Z-Score distress zone (-0.37 < 1.81, low-confidence approx)
- Penny stock risk ($0.005)
- RBA hiking (-3pts)
Risk Signals
- Below the 200-day average — the long-term trend is still working against it
- Piotroski F-Score weak (3/9, low-confidence approx)
- Deeply negative margins (-170%)
- Not enough chatter to gauge sentiment — defaulting to neutral
Expected next for IPD
Window: 1 Jul to 31 Dec
From a company announcement on 25 Feb 2026
Window: 22 Oct to 5 Nov
The last 6 moved IPD -16.1% on the day, on average — an observation, not a guide to what happens next.
Each date is labelled with how it is known. A date estimated from past filings is inferred from this company's own filing rhythm — it is not a confirmed date and not a statement about what the company intends to do. See the whole ASX calendar →
Recent Catalysts
NONE Appendix 4G and Corporate Governance Statement
NONE Appendix 4E
NONE FDA Clearance for Sarcopenia Risk Assessment Received
LOW 2026 Annual Report
Recent ASX Announcements
| 2026-08-27 | Appendix 4G and Corporate Governance Statement |
| 2026-08-27 | 2026 Annual Report |
| 2026-08-27 | Appendix 4E PRICE SENSITIVE |
| 2026-08-18 | FDA Clearance for Sarcopenia Risk Assessment Received |
| 2026-08-13 | ASX Listing Rule 7.16 Compliance |
Key Metrics
$18.3M
Market Cap
2.1M
Avg Volume
1.0x
Vol Ratio
$0.00 — $0.06
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-162.4%
ROE
-170.4%
Profit Margin
CANSLIM Analysis
| Factor | Rating | Detail | |
|---|---|---|---|
| C | Current EPS | fail | EPS Growth: 0% |
| A | Annual Earnings | fail | CAGR: 0% |
| N | New Highs / Catalysts | neutral | |
| S | Supply & Demand | neutral | Float: 92% |
| L | Leader vs Laggard | laggard | RS: 0 |
| I | Institutional Sponsorship | pass | Inst: 21% |
| M | Market Direction | neutral | Neutral |
Sector: Healthcare
110 tickers in this sector
View all Healthcare signals →Browse all ASX tickers A–Z →Track IPD and 2,200+ ASX stocks
Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.
No credit card required